Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TW3L
|
|||
| Former ID |
DIB010191
|
|||
| Drug Name |
CD20Bi aATC
|
|||
| Synonyms |
CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma); Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute
Click to Show/Hide
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
| Company |
Barbara Ann Karmanos Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Modulator | [1] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Modulator | [1] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.